Citizens Jmp Cuts Enovis (NYSE:ENOV) Price Target to $47.00

Enovis (NYSE:ENOV) had its target price lowered by Citizens Jmp from $55.00 to $47.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a market outperform rating on the stock.

A number of other equities research analysts also recently weighed in on ENOV. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company lowered their price target on Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Canaccord Genuity Group dropped their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, August 17th. BTIG Research reduced their price objective on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Enovis Price Performance

ENOV stock opened at $18.58 on Wednesday. The company’s 50-day moving average price is $25.50 and its two-hundred day moving average price is $24.20. The firm has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a 12 month low of $18.52 and a 12 month high of $34.28.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the prior year, the firm posted $0.79 EPS. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts anticipate that Enovis will post 3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oliver Engert acquired 5,140 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the acquisition, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 23,833 shares of company stock worth $469,455. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently made changes to their positions in ENOV. Arax Advisory Partners bought a new position in Enovis in the 4th quarter valued at approximately $29,000. Allworth Financial LP bought a new stake in Enovis during the 2nd quarter worth approximately $36,000. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Enovis in the 2nd quarter valued at approximately $48,000. Finally, Danske Bank A S acquired a new position in Enovis in the 3rd quarter valued at approximately $64,000. 98.45% of the stock is currently owned by institutional investors.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.